These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections. Nenoff P; Haustein UF; Hittel N Chemotherapy; 2004 Oct; 50(4):196-201. PubMed ID: 15452398 [TBL] [Abstract][Full Text] [Related]
24. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin. Barry AL; Fuchs PC J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012 [TBL] [Abstract][Full Text] [Related]
25. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens. Malmborg AS; Ahlén S Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030 [TBL] [Abstract][Full Text] [Related]
26. In vitro activity of T-3761, a new fluoroquinolone. Muratani T; Inoue M; Mitsuhashi S Antimicrob Agents Chemother; 1992 Oct; 36(10):2293-303. PubMed ID: 1332594 [TBL] [Abstract][Full Text] [Related]
27. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. Citron DM; Goldstein EJ; Merriam CV; Lipsky BA; Abramson MA J Clin Microbiol; 2007 Sep; 45(9):2819-28. PubMed ID: 17609322 [TBL] [Abstract][Full Text] [Related]
28. In vitro activity of E-4868, a new fluoroquinolone with a 7-azetidin ring, compared with ciprofloxacin, ofloxacin and fleroxacin. Mirelis B; Navarro F; Miró E; Coll R; Xicota MA; Prats G Drugs Exp Clin Res; 1995; 21(4):129-38. PubMed ID: 8529525 [TBL] [Abstract][Full Text] [Related]
29. Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria. Wakebe H; Mitsuhashi S Antimicrob Agents Chemother; 1992 Oct; 36(10):2185-91. PubMed ID: 1332589 [TBL] [Abstract][Full Text] [Related]
30. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates. Goldstein EJ; Citron DM; Tyrrell KL; Merriam CV Antimicrob Agents Chemother; 2013 Oct; 57(10):4872-6. PubMed ID: 23877700 [TBL] [Abstract][Full Text] [Related]
31. Comparative in vitro activity of lomefloxacin, a new difluoroquinolone. Clarke AM; Zemcov SJ Eur J Clin Microbiol Infect Dis; 1989 Feb; 8(2):164-8. PubMed ID: 2498101 [TBL] [Abstract][Full Text] [Related]
32. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections. Hoogkamp-Korstanje JA J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498 [TBL] [Abstract][Full Text] [Related]
34. In vitro activity of gatifloxacin, a new fluoroquinolone, against 204 anaerobes compared to seven other compounds. Dubreuil L; Behra-Miellet J; Neut C; Calvet L Clin Microbiol Infect; 2003 Nov; 9(11):1133-8. PubMed ID: 14616733 [TBL] [Abstract][Full Text] [Related]
35. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492. Harnett SJ; Fraise AP; Andrews JM; Jevons G; Brenwald NP; Wise R J Antimicrob Chemother; 2004 May; 53(5):783-92. PubMed ID: 15056651 [TBL] [Abstract][Full Text] [Related]
36. Antibacterial properties of AM-1155, a new 8-methoxy quinolone. Hosaka M; Kinoshita S; Toyama A; Otsuki M; Nishino T J Antimicrob Chemother; 1995 Aug; 36(2):293-301. PubMed ID: 8522459 [TBL] [Abstract][Full Text] [Related]
38. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests. Barry AL; Fuchs PC; Brown SD Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):305-9. PubMed ID: 10385024 [TBL] [Abstract][Full Text] [Related]
39. Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin). Cormican MG; Marshall SA; Jones RN Diagn Microbiol Infect Dis; 1995 Jan; 21(1):51-4. PubMed ID: 7789097 [TBL] [Abstract][Full Text] [Related]
40. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin. King A; Bethune L; Phillips I J Antimicrob Chemother; 1991 Nov; 28(5):719-25. PubMed ID: 1663930 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]